Biohit Oyj Valuation
Is BIOBV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOBV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIOBV (€2.3) is trading below our estimate of fair value (€4.41)
Significantly Below Fair Value: BIOBV is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOBV?
Key metric: As BIOBV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BIOBV's PE Ratio? | |
|---|---|
| PE Ratio | 21.1x |
| Earnings | €1.65m |
| Market Cap | €34.92m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.2x |
| Enterprise Value/EBITDA | 16.7x |
| PEG Ratio | 1.5x |
Price to Earnings Ratio vs Peers
How does BIOBV's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 40.5x | ||
REG1V Revenio Group Oyj | 37.6x | 19.0% | €718.1m |
A307280 Wonbiogen | 8.1x | n/a | ₩43.5b |
6730 Lagis Enterprise | 16.7x | n/a | NT$1.2b |
4744 CVC Technologies | 99.8x | n/a | NT$1.1b |
BIOBV Biohit Oyj | 21.1x | 14.5% | €34.9m |
Price-To-Earnings vs Peers: BIOBV is good value based on its Price-To-Earnings Ratio (21.1x) compared to the peer average (40.5x).
Price to Earnings Ratio vs Industry
How does BIOBV's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BIOBV is good value based on its Price-To-Earnings Ratio (21.1x) compared to the European Medical Equipment industry average (29.5x).
Price to Earnings Ratio vs Fair Ratio
What is BIOBV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 21.1x |
| Fair PE Ratio | 21x |
Price-To-Earnings vs Fair Ratio: BIOBV is expensive based on its Price-To-Earnings Ratio (21.1x) compared to the estimated Fair Price-To-Earnings Ratio (21x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Revenio Group Oyj
€718.1m
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally.
REG1V
€27.00
7D
-7.7%
1Y
10.3%
Optomed Oyj
€77.5m
Manufactures and sells handheld fundus cameras in Finland and internationally.
OPTOMED
€3.96
7D
-8.0%
1Y
30.7%